drugset / Trial / NCT01295372
Safety and Efficacy of Zicronapine in Patients With Schizophrenia
RandomizedParallel-groupDouble-blindTreatment
Summary
To assess the effect of zicronapine versus risperidone on metabolic parameters comprising body weight, body mass index (BMI), waist circumference, levels of fasting blood lipids and glucose during 6 months of treatment.
Timeline
- Start
- 2011-04
- Primary completion
- 2012-10
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Risperidone | Other / unclassified | 5 mg | Oral |
| Subject | Zicronapine | Small molecule | 7.5 mg | Oral |